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Abstract
Background: The aim of our study was to investigate the clinical features and expression levels of hypothalamic-
pituitary-gonadal axis-related hormone receptors in low-grade serous ovarian cancer (LGSC).
Methods: We retrospectively investigated the clinical features of 26 consecutive patients with LGSC who underwent
primary staging or debulking surgery between April 2005 and June 2013 in our center; concomitant primary high-
grade serous ovarian cancer (HGSC) patients were randomly selected at a 2:1 ratio for comparison. Tissue microarrays
were constructed from the LGSC and HGSC specimens, and the expression levels of six hormone receptors in the
hypothalamic pituitary-gonadal axis were analyzed by immunohistochemistry.
Results: The median (range) age of patients with LGSC was 54 (27–77) years. According to the FIGO staging system,
the cases were distributed as follows: stage I, 6 (23.1%); stage II, 0 (0%); stage III, 19 (73.1%); and stage IV, 1 (3.8%). The
2-year and 5-year overall survival rates for LGSC were 91.8% and 67.5%, respectively. The expression levels of the
hormone receptors were as follows: ER, 80.8%; PR, 34.6%; AR, 53.8%; FSHR, 84.0%; LHR, 65.4%; and GnRHR, 100%.
Hormone receptor-positive patients had a better prognosis compared with hormone receptor-negative patients, but
the difference was not significant.
Conclusions: Our study presented a higher overall survival rate and distinctive hormone receptor expression levels of
LGSC patients compared with the HGSC cohort. Patients with positive hormone receptor expression tended to have a
better prognosis than the corresponding hormone receptor negative patients.
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Background
Ovarian cancer is one of the most common and lethal
malignancies among females worldwide. The standard
treatment for ovarian cancer includes staging/debulking
surgery and individual platinum-based adjuvant chemo-
therapy, regardless of the tumor’s histologic subtype [1, 2].
However, previous studies have shown that epithelial ovar-
ian cancer is not a single disease but rather a group of
heterogeneous tumors based on distinct morphologic and
molecular genetic features [3]. The “one-size-fits-all-
concept” has been challenged for the treatment of some
rare ovarian cancer subtypes [4–6].
Low-grade serous ovarian cancer (LGSC) represents
less than 10% of serous ovarian cancers and is less sensi-
tive to conventional platinum-based chemotherapy com-
pared with high-grade serous ovarian cancers (HGSC)
[5–12]. Previous studies have shown considerable estro-
gen receptor (ER) and progesterone receptor (PR) ex-
pression levels in LGSC [13, 14], and hormone therapy
might be a promising alternative for recurrent LGSC
[15]. However, the expression levels of other hormone
receptors related to the hypothalamic-pituitary-gonadal
axis (androgen receptor (AR), follicle-stimulating hor-
mone receptor (FSHR), luteinizing hormone receptor
(LHR) and gonadotropin-releasing receptor (GnRHR)) in
LGSC, which could also mediate the effects of steroid
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hormones on the development and progression of ovar-
ian cancer, have not been shown. In addition, due to the
rarity of LGSC, studies on the clinicopathologic charac-
teristics of this type of ovarian cancer are quite limited.
The aims of this study were twofold: (1) to assess the
expression levels of hormone receptors related to the
hypothalamic-pituitary-gonadal axis and their prognostic
significance in LGSC and (2) to further delineate the clin-
ical features and prognosis of LGSC patients in comparison
with concomitant HGSC patients at a single institution.
Methods
Clinical data
This study was conducted according to the Declaration
of Helsinki and was approved by the Committee at
Fudan University Shanghai Cancer Center. Written in-
formed consent was obtained from all individual partici-
pants included in the study.
We retrospectively investigated women who under-
went primary staging or debulking surgery for LGSC at
Fudan University Shanghai Cancer Center with available
paraffin specimens between April 2005 and June 2013.
Patients were excluded if they had received neoadjuvant
therapy prior to the primary surgery, or were found to
have other histological diagnoses upon pathological re-
view. Concomitant primary HGSC patients were also in-
vestigated for comparison.
Clinical and pathological data were obtained from
medical records, cancer registries, and pathology reports.
Patient characteristics, including age, FIGO stage (ac-
cording to the 2005 system), surgical outcomes, date of
primary surgery, date of progression or recurrence, date
of last follow-up, and the patient’s disease status at last
contact were collected. Twenty-six consecutive LGSC
patients and 875 concomitant HGSC patients were iden-
tified, and we use SPSS software for simple random sam-
pling to select 52 HGSC patients at a 2:1 ratio for
comparison. All of the patients were followed up with
until December 31st, 2014.
R0 was defined as the absence of macroscopic residual
disease (RD) after surgery. Chemosensitivity was defined
as a time interval of 6 months or longer between the
completion of platinum-based chemotherapy and the
detection of relapse. Chemoresistance was defined as
disease progression during adjuvant platinum-based
chemotherapy or within the 6-month interval between
the completion of chemotherapy and the detection of
relapse. Overall survival (OS) was defined as the time
interval from the date of the primary surgery to the date
of death or the last follow-up.
Tissue microarray and immunohistochemistry
The histological diagnoses were based on the WHO cri-
teria [16], and all microscopic slides were reviewed by
two experienced gynecologic pathologists. A microarray
(1 mm) using triplicate tissue samples from each tumor
was prepared [17, 18]. Sections (3 μm) of the completed
tissue microarray were analyzed by standard immunohis-
tochemistry protocols. Immunohistochemical staining
was performed in all cases for ER and PR using a
Ventana Benchmark XT autostainer (Ventana Medical
Systems Inc., Tucson, AZ, USA). Staining for AR, FSHR,
LHR and GnRHR was performed using the Envision
horseradish peroxidase system following the manufac-
turer’s protocol (DAKO EnVision System K5007). The
details of the primary antibodies used in this study were
as follows: ER (Roche SP1), PR (Roche 1E2), AR (Abcam
ab133273, 1:100), FSH-R (Abcam ab150557, 1:100), LH-
R (Santa Cruz sc-25828, 1:40), and GnRH-R (Abcam
ab183079, 1:50). Negative (no primary antibody) and
positive (according to the primary antibody instructions)
controls were included in each staining experiment.
Results were independently judged, evaluated, and
scored by two experienced gynecologic pathologists that
were blinded to patient information. The results were
judged as the numerical mean of the values obtained
from the triplicate scores. The expression of hormone
receptors was determined using the following criteria:
ER, PR, and AR levels, >10% showing positive nuclear
staining of any intensity were defined as positive [19, 20].
FSHR and LHR levels, evaluation of the cytoplasmic
staining reaction was performed in accordance with the
immunoreactive score (IRS). The IRS was defined as the
staining intensity (SI) multiplied by the percentage of
positive cells (PP). SI was defined as 0 (negative), 1
(weak), 2 (moderate) and 3 (strong). PP was defined as 0
(negative), 1 (no more than 10% positive cells), 2 (11% to
50% positive cells), 3 (51% to 80% positive cells) and 4
(greater than 80% positive cells). IRS = SI × PP, IRS ≥ 3
was defined as positive [21].
The cytoplasmic staining of GnRHR was recorded as
negative, weak, moderate and strong. Staining of any in-
tensity was regarded as positive [22].
Statistical analyses
SPSS software (version 21.0) and GraphPad Prism (ver-
sion 6.0) were used for the statistical analyses. Descrip-
tive statistics were used for the demographic data and
were summarized as the medians with ranges or the
frequencies with percentages. The categorical data were
compared with chi-squared or Fisher’s exact tests as
appropriate. OS were analyzed with the Kaplan-Meier
method, log-rank tests and cox regression analyses for
univariate analyses. No significant impact of clinicopatho-
logic parameters on OS was observed in the univariate ana-
lyses, so multivariate analysis was not performed. P < 0.05
was considered statistically significant, and all re-
ported p-values were 2-sided.
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Results
Patient clinical features
A total of 901 serous ovarian cancer patients received
their primary surgery at our institution. Twenty-six (2.9%)
of these cases were LGSC and 875 (97.1%) were HGSC.
Among them, 52 primary HGSC patients were randomly
selected at a 2:1 ratio for comparison. The clinical features
of LGSC cases are listed in Table 1. The clinicopathologic
features of the LGSC and HGSC cohorts are compared in
Table 2.
More LGSC patients presented with an early FIGO
stage compared to HGSC patients (p = 0.002). The LGSC
cases were distributed as follows: stage I, 6 (23.1%); stage
II, 0; stage III, 19 (73.1%); and stage IV, 1 (3.8%). The
distribution of HGSC FIGO stage was as follows: stage I,
0 (0%); stage II, 2 (3.8%); stage III, 44 (84.6%); and stage
IV, 6 (11.5%). There were no significant differences in
terms of other basic clinical features including age,
family history, surgical outcomes and chemosensitivity
between both groups. The median (range) age of LGSC
patients was 54 (27–77) years. At the time of surgery, 13
(50%) LGSC patients were debulked to no visible
residual disease, and 9 (34.6%) had <1 cm but retained
macroscopic disease. With one exception, all LGSC pa-
tients received postoperative platinum-based chemother-
apy; 15 (57.7%) were platinum sensitive.
The median (range) follow-up time for LGSC patients
was 30 (12–87) months. In the overall cohort, a total of
five (19.2%) deaths were documented. The median
follow-up time for the matched HGSC cohort was 26
(5–99) months. Twenty-four (46.2%) deaths were docu-
mented. The overall survival curves for LGSC and
HGSC patients are shown in Fig. 1. The LGSC group
presented a longer overall survival rate than the HGSC
group, which approached significance (p = 0.06). The 2-
year and 5-year OSs for LGSC were 91.8% and 67.5%,
respectively. The 2-year and 5-year OSs for HGSC were
67.3% and 47.9%, respectively.
We then estimated some potential prognostic clinical
factors in LGSC patients. Five out of 20 patients at an
Table 1 Clinical features of LGSC cases
Case no Age FIGO stage Residual disease Chemotherapy Chemosensitivity Follow-up (months) Survival Outcomes
1 57 IIIC R0 Y Y 21 Censored
2 39 IIIC ≥1 cm Y Y 20 Alive
3 77 IC R0 NA NA NA Censored
4 27 IIIC ≥1 cm Y N 18 Died
5 46 IIIC ≥1 cm Y N 32 Alive
6 68 IIIC 0.1-1 cm Y NA 12 Died
7 49 IIIC 0.1-1 cm Y N 52 Alive
8 42 IIIC ≥1 cm Y N 13 Censored
9 76 IIIB R0 Y Y 22 Alive
10 57 IIIC 0.1-1 cm Y Y 20 Alive
11 54 IIIC 0.1-1 cm Y N 19 Alive
12 75 IIIC R0 Y N 70 Alive
13 61 IB R0 Y NA 19 Censored
14 39 IB R0 Y Y 56 Alive
15 54 IIIB 0.1-1 cm Y Y 53 Alive
16 34 IC R0 Y Y 30 Alive
17 60 IIIC R0 Y Y 41 Alive
18 40 IA R0 Y Y 20 Alive
19 40 IA R0 Y Y 59 Alive
20 53 IIIC 0.1-1 cm Y N 30 Died
21 57 IIIC R0 Y Y 22 Alive
22 43 IIIC 0.1-1 cm Y Y 45 Alive
23 35 IIIC R0 Y Y 87 Alive
24 55 IIIC R0 Y Y 50 Alive
25 69 IV 0.1-1 cm Y Y 27 Died
26 62 IIIC 0.1-1 cm Y N 52 Died
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advanced FIGO stage (III and IV) died, but no deaths
were observed in patients with an early FIGO stage (I
and II). Similar results were found for residual disease
(R0 vs 0.1–1 cm vs ≥1 cm: 0/13 vs 4/9 vs 1/4, p = 0.063).
Patients with chemosensitive disease had a lower death
rate compared to those with chemoresistant disease
(6.7% vs 37.5%, p = 0.117) (Table 3).
Hormone receptor expression
Representative images of LGSC and HGSC hormone re-
ceptor staining are shown in Fig. 2 and Additional file 1:
Figure S1. The hormonal receptor expression levels of
both groups are shown in Table 2 and Additional file 2:
Figure S2. A total of 21 (80.8%) LGSC patients were ER
positive, compared with 70.6% of HGSC patients (p =
0.417). LGSC patients presented much higher expression
levels of PR (34.6% vs 9.8%, p = 0.012), FSHR (84.0% vs
54.9%, p = 0.021), LHR (65.4% vs 35.3%, p = 0.015) and
GnRHR (100% vs 81.6%, p = 0.026) compared to HGSC
patients. The AR expression level was also higher in LGSC
than in HGSC patients, but the difference was not signifi-
cant (53.8% vs 33.3%, p = 0.089).
Associations of clinical parameters and hormone re-
ceptor expression in LGSC are shown in Additional file
3: Table S1. More patients in the R0 group showed ER
positive compared with those who had 0.1–1 cm and
≥1 cm residual disease. There are no other significant
Table 2 Patient characteristics of LGSC compared with HGSC
Clinicopathologic features LGSC HGSC P value
Age median(range) 54 (27-77) 56 (36-77) 0.075
FIGO I 6 23.1% 0 0.0% 0.002
II 0 0.0% 2 3.8%
III 19 73.1% 44 84.6%
IV 1 3.8% 6 11.5%
Family history Yes 4 15.4% 12 23.1% 0.557
No 22 84.6% 40 76.9%
Cytoreduction R0 13 50.0% 16 30.8% 0.25
0.1-1 cm 9 34.6% 24 46.2%
≥1 cm 4 15.4% 12 23.1%
Chemosensitivity Yes 15 57.7% 33 63.4% 0.656
No 8 30.8% 16 30.8%
NA 3 11.5% 3 5.8%
ER + 21 80.8% 36 70.6% 0.417
- 5 19.2% 15 29.4%
PR + 9 34.6% 5 9.8% 0.012
- 17 65.4% 46 90.2%
AR + 14 53.8% 17 33.3% 0.089
- 12 46.2% 34 66.7%
FSHR + 21 84.0% 28 54.9% 0.021
- 4 16.0% 23 45.1%
LHR + 17 65.4% 18 35.3% 0.015
- 9 34.6% 33 64.7%
GnRHR + 24 100.0% 40 81.6% 0.026
- 0 0.0% 9 18.4%
Fig. 1 The Kaplan-Meier curve of overall survival for patients with
ovarian LGSC and HGSC (P = 0.06)
Table 3 Risk of death categorized by clinicopathologic
parameters
Characteristics Overall death P (log rank test)




Family history Yes 0/4 0.0% 0.339
No 5/22 22.7%
Cytoreduction R0 0/13 0.0% 0.063
0.1-1 cm 4/9 44.4%
≥1 cm 1/4 25.0%
Chemosensitivity Yes 1/15 6.7% 0.117
No 3/8 37.5%
NA 1/3 33.3%
ER + 3/21 14.3% 0.173
- 2/5 40.0%
PR + 0/9 0.0% 0.148
- 5/17 29.4%
AR + 2/14 14.3% 0.508
- 3/12 25.0%
FSHR + 4/21 19.0% 0.862
- 1/4 25.0%
LHR + 3/17 17.6% 0.88
- 2/9 22.2%
GnRHR + 4/24 16.7% NA
- 0/0 -
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differences between hormone receptor expression and
clinical parameters.
Data for hormone receptor expression and patient prog-
nosis were also analyzed. The risk of death was higher in
hormone receptor negative patients than hormone recep-
tor positive patients: ER- vs ER+ 40.0% vs 14.3%, PR- vs
PR+ 29.4% vs 0%, AR- vs AR+ 25.0% vs 14.3%, FSHR- vs
FSHR+ 25.0% vs 19.0%, LHR- vs LHR+ 22.2% vs 17.6%.
However, the differences were not significant in univariate
analyses (Fig. 3 and Additional file 3: Table S2). Similarly,
there were no significant prognostic factors for HGSC in
univariate analyses (Additional file 3: Table S3).
Discussion
In this mono-institutional study, we investigated the
clinicopathologic features of 26 LGSC patients with a
higher overall survival rate and distinctive hormone recep-
tor expression levels compared with the HGSC cohort. Six
hormone receptors related to the hypothalamic-pituitary-
gonadal axis were found to be highly expressed in LGSC.
Patients with positive hormone receptor expression
tended to have a better prognosis than the corresponding
hormone receptor negative patients.
In our cohort, LGSC constituted 2.9% of all serous
ovarian cancer, highlighting the rarity of this neoplasm.
The incidence rate was quite lower than that reported
by other investigators [7, 9, 10, 23]. There was a poten-
tial selection bias because we excluded all referral/con-
sultation cases sent to our hospital as well as those who
received neoadjuvant chemotherapy. Another explan-
ation may be incidence variation among different
ethnicities.
We found that LGSC tended to present with an ad-
vanced FIGO stage (FIGO stage III/IV vs FIGO stage I:
76.9% vs 23.1%), although the rate was lower than HGSC.
This finding is in accordance with the distribution
Fig. 2 Representative positive staining for ER (a), PR (b), AR (c), FSHR (d), LHR (e) and GnRHR (f) at 400 ×magnification (LGSC)
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obtained in previous studies [23, 24]. Moreover, although
LGSC is known to be less sensitive to conventional
platinum-based chemotherapy compared to high-grade
serous ovarian cancers (HGSC) in the literature, no exact
data have been reported [10, 11, 25]. We reported a plat-
inum sensitivity rate of 57.7%, which made the data for
the LGSC study more complete. However, our study did
not find any significant difference between the two groups.
This may be due to the limited number of cases.
The 5-year overall survival rate of LGSC ranges from
61 to 71% in the literature [6, 23, 24, 26]; the 5-year OS
observed in our cohort was 67.5%. Similar to previous
studies, we confirmed a higher overall survival rate in
LGSC compared with HGSC, although this only
approached significance [6, 23, 26–28]. In this study, we
evaluated the survival in both groups without taking into
account FIGO stage, cytoreduction outcomes or other
clinicopathologic features in our limited number of
study cases.
Furthermore, although several studies have investi-
gated the significance of hormone receptor expression in
ovarian cancer, the results are inconsistent, and most
studies combined all disease subtypes [17, 29–34]. Stud-
ies evaluating the subtype-specific influence on hormone
receptor expression are urgently needed. We have previ-
ously reported the prognostic significance of hormone
receptor expression in HGSC, which is the major sub-
type of ovarian cancer [35]. As a distinctively different
but rare tumor, reports on hormone receptor expression
in LGSC are scarce. In our study, LGSC presented sig-
nificantly greater hormone receptor levels compared to
HGSC. We found substantial expression levels of ER
(80.8%) and PR (34.6%) in LGSC, which is in accordance
with previous studies [13, 14]. In addition, we reported
Fig. 3 Kaplan-Meier curves of overall survival in LGSC patients stratified by hormone receptor expression (a ER, b PR, c AR, d FHSR, e LHR,
g GnRHR)
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high expression levels of other hormone receptors (AR,
FSHR, LHR and GnRHR) related to the hypothalamic-
pituitary-gonadal axis for the first time. Interestingly,
hormone receptor negative LGSC patients had a higher
risk of death compared to hormone receptor positive
LGSC patients. Although the survival advantages were
not significant, this could indicate the predictive value of
these biomarkers. Furthermore, hormone therapy and
targeted therapy may be promising alternatives for LGSC
treatment. Gershenson et al. [15] reported moderate
anti-tumor activity of hormone therapy in patients with
recurrent LGSC. FSHR or GnRHR targeted agents have
been developed by using corresponding ligands, and
phase II studies have shown their promising applications
for ovarian cancer [36, 37]. The high expression levels of
hormone receptors in our study indicate the potential
application of the above treatment in LGSC.
Our study is limited because it is a retrospective study
that is dependent on accurate medical records, and thus
may have potential recall bias. Although there were only
26 patients in our study, due to the rarity of this tumor,
any data related to the clinicopathologic features of
LGSC should be reported.
Conclusions
In conclusion, our study presented a higher overall sur-
vival rate and distinctive hormone receptor expression
levels of LGSC patients compared with the HGSC co-
hort. Patients with positive hormone receptor expression
tended to have a better prognosis than the correspond-
ing hormone receptor negative patients. Future pro-
spective cooperative multicenter studies are needed to
further identify more details about the clinicopathologic
characteristics of LGSC.
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Additional file 1: Figure S1. Representative positive staining for ER (A),
PR (B), AR (C), FSHR (D), LHR (E) and GnRHR (F) at 400x magnification
(HGSC). (TIFF 2702 kb)
Additional file 2: Figure S2. Differences of hormone receptor
expression levels between LGSC and HGSC groups: ER (A), PR (B), AR (C),
FSHR (D), LHR(E) and GnRHR (F). (TIFF 180 kb)
Additional file 3: Table S1. Associations of clinical parameters with
hormone receptor expression in LGSC. Table S2. Univariate analyses of
risk factors for OS in LGSC cases. Table S3. Univariate analyses of risk
factors for OS in HGSC cases. (DOC 95 kb)
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